Adverse events in IBD therapy: the 2018 update

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Increasing prevalence of Crohn's disease and ulcerative colitis.
• Rising use of immunomodulator and biologic therapies for IBD.
• Associated adverse events range from mild to severe, including infections and malignancies.

Purpose of the Study:

• To provide an updated discussion on adverse events associated with key IBD therapies.
• To review the risk profile of infliximab biosimil.
• To emphasize risk-benefit discussions and personalized treatment selection.

Main Methods:

• Literature review of adverse events for immunomodulators, anti-TNF-α, anti-integrin, and anti-IL 12/IL-23 therapies.
• Analysis of the risk profile of infliximab biosimilar.
• Synthesis of expert commentary on therapeutic selection.

Main Results:

• Identified adverse events linked to various immunomodulator and biologic agents used in IBD.
• Detailed the risk profile of widely available infliximab biosimilar.
• Highlighted the importance of individualized risk assessment.

Conclusions:

• Providers must discuss specific medication risks and benefits with patients.
• Individualized risk factors are critical in selecting IBD therapies.
• Drug monitoring and shared decision-making enhance personalized IBD management.